Lead Product(s) : Tafoxiparin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pregnant women will be randomized to either subcutaneous injection of tafoxiparin and standard of care or only standard of care, which is usually symptomatic treatment with anti-hypertensive drugs.
Product Name : DF01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : Tafoxiparin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafoxiparin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of the study was to document the effect of tafoxiparin on cervical ripening measured as the degree of ripening according to an internationally established scale, the Bishop score.
Product Name : DF01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Tafoxiparin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopregnanolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Asarina Pharma Reports Topline Results from Phase Iib Study in PMDD
Details : Substantial reduction in PMDD symptoms was achieved across the patient population, but, in comparison to placebo, primary and secondary endpoints were not statistically significant.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : Allopregnanolone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable